Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CYAN

Cyanotech (CYAN) Stock Price, News & Analysis

Cyanotech logo

About Cyanotech Stock (NASDAQ:CYAN)

Advanced Chart

Key Stats

Today's Range
$0.33
$0.34
50-Day Range
$2.83
$3.26
52-Week Range
$2.37
$6.29
Volume
22,450 shs
Average Volume
3,483 shs
Market Capitalization
$2.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cyanotech Corp. engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. Its products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant, which is used as a human dietary supplement and dietary ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye, joint, and immune health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company was founded by Gerald R. Cysewski in 1983 and is headquartered in Kailua-Kona, HI.

Receive CYAN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyanotech and its competitors with MarketBeat's FREE daily newsletter.

CYAN Stock News Headlines

Q3 2025 Cyanotech Corp Earnings Call
Real Americans Don’t Wait on Wall Street’s Next Move
What's happening in the markets right now should concern every freedom-loving American who's worked hard and saved smart. Your 401(k) doesn't deserve to be dragged through the mud by tariffs, trade wars, reckless spending, and political standoffs. And you don't have to stand by while Wall Street plays roulette with your future.
See More Headlines

CYAN Stock Analysis - Frequently Asked Questions

Cyanotech Co. (NASDAQ:CYAN) posted its quarterly earnings results on Tuesday, November, 12th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter. The biotechnology company earned $5.85 million during the quarter. Cyanotech had a negative trailing twelve-month return on equity of 44.71% and a negative net margin of 19.50%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cyanotech investors own include AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), Allena Pharmaceuticals (ALNA), Clarivate (CCC), Karyopharm Therapeutics (KPTI) and Madrigal Pharmaceuticals (MDGL).

Company Calendar

Last Earnings
11/12/2024
Today
4/19/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medicinals & botanicals
Sub-Industry
N/A
Current Symbol
NASDAQ:CYAN
Employees
95
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-5,270,000.00
Pretax Margin
-19.48%

Debt

Sales & Book Value

Annual Sales
$23.07 million
Price / Cash Flow
N/A
Book Value
$1.33 per share
Price / Book
0.25

Miscellaneous

Free Float
5,074,000
Market Cap
$2.41 million
Optionable
Not Optionable
Beta
-0.11
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:CYAN) was last updated on 4/19/2025 by MarketBeat.com Staff
From Our Partners